Target family: Lysophospholipid (S1P) receptors (type: gpcr)
Target: S1P<sub>1</sub> receptor

Ligand: A-971432 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.440000057220459 pIC50
Reference (Journal): Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.
Published in: J Med Chem

Ligand: AFD(R) (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Published in: J Biol Chem

Ligand: amiselimod phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10.119999885559082 pEC50
Reference (Journal): Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.
Published in: Br J Pharmacol

Ligand: amiselimod phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 10.890000343322754 pEC50
Reference (Journal): Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells.
Published in: PLoS One

Ligand: ASP4058 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.130000114440918 pIC50
Reference (Journal): ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
Published in: PLoS ONE

Ligand: AUY954 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pEC50
Reference (Journal): A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model.
Published in: Chem Biol

Ligand: AUY954 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pEC50
Reference (Journal): A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model.
Published in: Chem Biol

Ligand: BMS-986104 derivative 12 (Synthetic organic)
Interaction type: Agonist
Action: Biased agonist
Ligand approved: no
Primary target: no
Median affinity: 8.680000305175781 pEC50
Reference (Journal): Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.
Published in: J Med Chem

Ligand: BMS-986104 derivative 24 (Synthetic organic)
Interaction type: Agonist
Action: Biased agonist
Ligand approved: no
Primary target: no
Median affinity: 8.680000305175781 pEC50
Reference (Journal): Bicyclic Ligand-Biased Agonists of S1P<sub>1</sub>: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.
Published in: J Med Chem

Ligand: BMS-986166 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 9.220000267028809 pEC50
Reference (Journal): Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Modulator Advanced into Clinical Trials.
Published in: J Med Chem

Ligand: cenerimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 9 pEC50
Reference (Journal): Cenerimod, a novel selective S1P<sub>1</sub>receptor modulator with unique signaling properties.
Published in: Pharmacol Res Perspect

Ligand: compound 26 [PMID: 16190743] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 9.22 pIC50
Reference (Journal): Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3.
Published in: J Med Chem

Ligand: compound 43 [PMID: 26751273] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 8.800000190734863 pEC50
Reference (Journal): Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
Published in: J Med Chem

Ligand: CYM5181 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.470000267028809 pEC50
Reference (Journal): Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions.
Published in: Mol Pharmacol

Ligand: CYM5442 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.90999984741211 pEC50
Reference (Journal): Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions.
Published in: Mol Pharmacol

Ligand: etrasimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2023)
Primary target: yes
Median affinity: 8.210000038146973 pEC50
Reference (Journal): Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
Published in: ACS Med Chem Lett

Ligand: etrasimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity: 9.239999771118164 pEC50
Reference (Journal): Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells.
Published in: PLoS One

Ligand: fingolimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2010), EMA (2011)
Primary target: yes
Median affinity: 6.079999923706055 pIC50
Reference (Journal): A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
Published in: J Med Chem

Ligand: fingolimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pEC50
Reference (Journal): Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: fingolimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: fingolimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pIC50
Reference (Journal): Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: fingolimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Published in: J Biol Chem

Ligand: fingolimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Published in: J Biol Chem

Ligand: fingolimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice.
Published in: J Pharmacol Exp Ther

Ligand: GSK2018682 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pEC50
Reference (Journal): Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers.
Published in: Clin Pharmacol Drug Dev

Ligand: icanbelimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.010000228881836 pEC50
Reference (Patent): Immune adjustment compound, use thereof and pharmaceutical composition comprising same

Ligand: mocravimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.069999694824219 pEC50
Reference (Journal): A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice.
Published in: J Pharmacol Exp Ther

Ligand: mocravimod-phosphate (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 8.760000228881836 pEC50
Reference (Journal): Use of sphingosine-1-phosphate 1 receptor agonist, KRP-203, in combination with a subtherapeutic dose of cyclosporine A for rat renal transplantation.
Published in: Transplantation

Ligand: NIBR-0213 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pIC50
Reference (Journal): A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.
Published in: Chem Biol

Ligand: NIBR-0213 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.430000305175781 pKd
Reference (Journal): A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis.
Published in: Chem Biol

Ligand: ozanimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2020)
Primary target: yes
Median affinity: 9.800000190734863 pEC50
Reference (Journal): Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
Published in: Br J Pharmacol

Ligand: ozanimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2020)
Primary target: no
Median affinity: 9.479999542236328 pEC50
Reference (Journal): Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells.
Published in: PLoS One

Ligand: ozanimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2020)
Primary target: yes
Median affinity: 9.390000343322754 pEC50
Reference (Journal): Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
Published in: Br J Pharmacol

Ligand: ozanimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2020)
Primary target: yes
Median affinity: 9.800000190734863 pEC50
Reference (Patent): Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis.

Ligand: ozanimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2020)
Primary target: yes
Median affinity: 9.800000190734863 pEC50
Reference (Journal): Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions.
Published in: Mol Pharmacol

Ligand: ponesimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: EMA & FDA (2021)
Primary target: yes
Median affinity: 8.039999961853027 pEC50
Reference (Journal): 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.
Published in: J Med Chem

Ligand: RP-001 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 11.050000190734863 pEC50
Reference (Journal): Actions of a picomolar short-acting S1P₁ agonist in S1P₁-eGFP knock-in mice.
Published in: Nat Chem Biol

Ligand: RP-101075 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 9.569999694824219 pEC50
Reference (Journal): Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.
Published in: PLoS ONE

Ligand: SAR247799 (Synthetic organic)
Interaction type: Agonist
Action: Biased agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): A G protein-biased S1P<sub>1</sub> agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers.
Published in: Sci Signal

Ligand: SEW2871 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.679999828338623 pEC50
Reference (Journal): Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
Published in: J Biol Chem

Ligand: SEW2871 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions.
Published in: Mol Pharmacol

Ligand: SEW2871 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
Published in: J Biol Chem

Ligand: SEW2871 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
Published in: J Biol Chem

Ligand: siponimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2019), EMA (2020)
Primary target: no
Median affinity: 10.109999656677246 pEC50
Reference (Journal): Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells.
Published in: PLoS One

Ligand: siponimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2019), EMA (2020)
Primary target: yes
Median affinity: 9.399999618530273 pEC50
Reference (Journal): Metabolism and Disposition of Siponimod, a Novel Selective S1P<sub>1</sub>/S1P<sub>5</sub> Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism.
Published in: Drug Metab Dispos

Ligand: siponimod (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2019), EMA (2020)
Primary target: yes
Median affinity: 9.399999618530273 pEC50
Reference (Journal): Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.
Published in: ACS Med Chem Lett

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Published in: J Biol Chem

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.850000381469727 pEC50
Reference (Journal): Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
Published in: J Biol Chem

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.850000381469727 pEC50
Reference (Journal): A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model.
Published in: Chem Biol

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells.
Published in: J Biol Chem

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate.
Published in: J Biol Chem

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model.
Published in: Chem Biol

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P5 (Edg-8): structure-activity relationship of sphingosine1-phosphate receptors.
Published in: Biochemistry

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition.
Published in: J Biol Chem

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Identification of Leu276 of the S1P1 receptor and Phe263 of the S1P3 receptor in interaction with receptor specific agonists by molecular modeling, site-directed mutagenesis, and affinity studies.
Published in: Mol Pharmacol

Ligand: sphingosine 1-phosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 9.539999961853027 pEC50
Reference (Journal): Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells.
Published in: PLoS One

Ligand: SPM-354 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pA2
Reference (Journal): Bitopic Sphingosine 1-Phosphate Receptor 3 (S1P3) Antagonist Rescue from Complete Heart Block: Pharmacological and Genetic Evidence for Direct S1P3 Regulation of Mouse Cardiac Conduction.
Published in: Mol Pharmacol

Ligand: ST-1478 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Novel compounds with dual S1P receptor agonist and histamine H<sub>3</sub> receptor antagonist activities act protective in a mouse model of multiple sclerosis.
Published in: Neuropharmacology

Ligand: ST-1505 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Novel compounds with dual S1P receptor agonist and histamine H<sub>3</sub> receptor antagonist activities act protective in a mouse model of multiple sclerosis.
Published in: Neuropharmacology

Ligand: ST-2191 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.699999809265137 pEC50
Reference (Journal): ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P<sub>1</sub> Agonist and Functional Antagonist Potency In Vitro and In Vivo.
Published in: Molecules

Ligand: VPC03090-P (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.
Published in: J Pharmacol Exp Ther

Ligand: VPC03090-P (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of a sphingosine 1-phosphate receptor antagonist prodrug.
Published in: J Pharmacol Exp Ther

Ligand: VPC23019 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.860000133514404 pKi
Reference (Journal): Sphingosine 1-phosphate analogs as receptor antagonists.
Published in: J Biol Chem

Ligand: VPC44116 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.570000171661377 pIC50
Reference (Journal): Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists.
Published in: Bioorg Med Chem

Ligand: VPC44116 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pKi
Reference (Journal): Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists.
Published in: Bioorg Med Chem

Ligand: W146 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.110000133514404 pKi
Reference (Journal): Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo.
Published in: Nat Chem Biol